We are excited to announce the first members of our Brain Trust, a group of advisors and colleagues who will help PALTOWN and its communities thrive.
Meet our Brain Trust
Chelsea Boet, MDDirector
Chris Heery, MDDirector
Kamala Maddali, DVM, Ph.D.Director
Chris Yoo, Ph.D.Director
Dr. Scott Kopetz
Dr. Christopher Lieu
Stephen Schoenberger, Ph.D.
Chelsea Boet, MD
Dr. Chelsea Boet is a primary care physician board certified in Internal Medicine and Pediatrics. She cares for patients from birth through end of life, specializing in preventative care and management of chronic medical illnesses. Special interests include breastfeeding medicine. Dr. Boet earned her BA from Kalamazoo College, and completed her MD training at Wayne State University School of Medicine. She practices medicine full time in Grand Rapids, MI.
Chris Heery, MD
Dr. Christopher Heery is the Chief Medical Officer for Bavarian Nordic where he oversees the clinical development of BN’s pipeline, comprising therapeutic cancer vaccines and vaccines for prevention of infectious diseases. He is a medical oncologist by training. He trained at the National Cancer Institute in the Laboratory of Tumor Immunology and Biology, where he went on to be the Head of the Clinical Trials group in that translational ImmunoOncology-focused branch. He has personally run a wide variety of immunotherapy trials using a variety of first-in-human agents including therapeutic cancer vaccines, checkpoint inhibitors, antibody-cytokine conjugates, and cytokine targeting antibodies. His trial experience also includes combination strategies in IO and IO with standard therapies based on mechanistic rationale.
Kamala Maddali, DVM, Ph.D.
Kamala Maddali, DVM, Ph.D.
Vice President, Biopharma Collaborations & Companion Diagnostics, Cancer Genetics
Dr. Maddali’s mantra for leadership is to “spread some sunshine” by being passionate and positive about her commitment to patient’s health via novel testing solutions for precision medicine.
While at Merck, Dr. Maddali played a pivotal role as a biomarker scientist understanding the various pharmacological and toxic effects of investigational drugs across multiple therapeutic areas in oncology, neurology and obesity disorders.
She also has extensive experience as a chief scientific commercial liaison for precision medicine at top-tier central laboratories and reference laboratories, including Quintiles and Quest Diagnostics.
At Cancer Genetics, she has initiated a biopharma collaboration campaign, implementing strategic initiatives to foster positive growth of the company through the provision of high-quality, innovative, responsive services. Her vision is to ensure that the patient’s voice is heard and her goal is to help patients and pharma partners implement the right test for the right patient and innovate the right drugs for improving global community health.
Dr. Maddali’s work to realize this vision includes the upcoming “Adopt a patient program,” which will help screen women in underserved communities in Asia for early cancer diagnosis. She is a board member for “Cancer NJ”, a South Asian cancer patient advocacy organization working to foster knowledge about cancer diagnosis and prevention, and is a scientific advisor to “Beat Cancer,” which works to help prevent cancer through lifestyle changes. Dr. Maddali also empowers students as a scientific educational mentor and helps them to successfully navigate their educational goals by staying committed to healthcare.
Dr. Maddali was the 2016 Healthcare Heroes Finalist Award for “Innovation-Individual” category at NJBIZ.
Dr. Maddali serves as a Vice Chair for the Women in Bio (WIB) Philadelphia chapter. The Women In Bio organization promotes careers, leadership, and entrepreneurship for women in the life sciences.
Dr. Maddali is very committed to save lives, to empower those affected by cancer, and to inspire younger generations to stay committed to healthcare education and be the future of global community health. She holds a Ph.D. in Pharmacology from University of Missouri-Columbia and a DVM Veterinary Medicine from Acharya N.G. Ranga Agricultural University in India.
Chris Yoo, Ph.D.
Chris has over 20 years of experience in advancing cutting-edge biomedical information technology. He is Founder, President & CEO of Systems Imagination, Inc., which offers advanced cognitive computing technology and artificial intelligence methodologies to translate big data into valuable insights. Chris was instrumental at IBM as Head of Strategy and Planning in the Information Based Medicine group, where he developed initiatives to target the growing field of personalized medicine as new molecular therapeutics were first being used to treat cancer. He has also held leadership positions at healthcare and technology companies including Systems Oncology, Cisco, Oracle, and Applied Biosystems.
As a serial entrepreneur, Chris has created value in new companies that accelerate the adoption of personalized medicine through genomics and cognitive computing. He has founded and successfully engineered the exit of startups including MedTrust Online, LLC, the world’s first largest online community of cancer doctors treating difficult cases with molecular medicine. He continues to create new value in innovative ventures at the intersection of Healthcare & Life Sciences and Information Technology.
Dr. Yoo is an Adjunct Faculty member of the Department of Biomedical Informatics of Arizona State University. He is a recipient of the Jane Coffin Childs Memorial Cancer Research Award for his postdoctoral fellowship at UC Berkeley, and he received his PhD in Cell and Molecular Biology from Yale University.
Dr. Scott Kopetz
Scott Kopetz, M.D., Ph.D., Associate Professor, GI Medical Oncology, University of Texas MD Anderson Cancer Center
Dr. Scott Kopetz graduated Summa Cum Laude from Vanderbilt University with a bachelor’s degree in Biomedical Engineering/Electrical and received his medical degree from Johns Hopkins School of Medicine. He obtained his residency training in Internal Medicine at Duke University Medical Center, followed by a medical oncology fellowship at MD Anderson Cancer Center. Dr. Kopetz joined MD Anderson Cancer Center in 2006 as an Assistant Professor of Medicine in the Department of Gastrointestinal Medical Oncology. He subsequently completed a Ph.D. at MD Anderson in cancer biology with thesis focus on mechanisms of chemotherapy resistance in colorectal cancer. Dr. Kopetz is board-certified in Internal Medicine and in Medical Oncology. He has authored over 100peer-reviewed articles in respected scientific journals such as Journal of Clinical Oncology, Lancet,Cancer Research, Cancer, Clinical Cancer Research, and JAMA, and is a senior editor for Clinical Cancer Research, and editorial board member on Journal of Clinical Oncology and JNCI. He is vice chair for colon cancer research in the NSABP/RTOG cooperative group, and member of the NIH Gastrointestinal Oncology Steering Committee. In addition, he was a recipient of peer-reviewed grants from American Society of Clinical Oncology and the National Institute of Health, among others. He is the principal investigator of several Phase I and II clinical trials, including the Assessment of Targeted Therapies Against Colorectal Cancer (ATTACC) study, a novel biomarker enrichment program for colorectal cancer. His research interests include the biology of refractory colorectal cancer and the development of novel therapeutics for molecularly distinct subsets of colorectal cancer patients.
Dr. Christopher Lieu
Director, Gastrointestinal Medical Oncology, University of Colorado School of Medicine
Deputy Associate Director for Clinical Research, University of Colorado School of Medicine
Dr. Lieu joined the University of Colorado School of Medicine faculty as an Assistant Professor of Medicine in July 2011. He trained in internal medicine at the University of Colorado, where he also served as a Chief Medical Resident. He completed his fellowship training in medical oncology at the University of Texas MD Anderson Cancer Center and served as the Chief Medical Oncology Fellow in 2010. He currently serves as the Director of GI Medical Oncology at the University of Colorado Cancer Center, is a member of the National Cancer Institute Colon Cancer Task Force, and serves on the National Comprehensive Cancer Network (NCCN) Panel for Neuroendocrine Cancers.
Dr. Lieu is a member of the Developmental Therapeutics (phase I clinical trials) and Gastrointestinal (GI) Medical Oncology Program. These comprehensive programs include multidisciplinary cancer clinics, tumor boards, and research endeavors. Dr. Lieu is interested in resistance mechanisms to targeted therapy in GI cancers, and he was awarded the Conquer Cancer Foundation Career Development Award and a NIH K23 grant to study targeted therapies in colorectal cancer. Dr. Lieu is also investigating novel therapeutic strategies to more effectively treat and prevent colorectal cancer in young adults.
Stephen Schoenberger, Ph.D.
Professor, Laboratory of Cellular Immunology
La Jolla Institute for Allergy and Immunology
Director of Translational Science, San Diego Center for Cancer
Head of Cancer Vaccines, Human Longevity, Inc
Dr. Schoenberger is a Professor in the Laboratory of Cellular Immunology and Co-Director of the San Diego Center for Personalized Cancer Immunotherapy, as well as Adjunct Professor of Medicine in the Division of Hematology and Oncology at the UCSD Moores Cancer Center. He received his Ph.D. in Microbiology and Molecular Genetics from UCLA in 1993 and completed postdoctoral training in Immunohematology and Tumor Immunology at the University of Leiden in The Netherlands. Dr. Schoenberger was appointed to LIAI’s faculty in 1998 as an Assistant Professor, was promoted to
Associate Professor in 2002, gained Tenure in 2005, and became a Professor in 2007. He is a recipient of Scholar Awards from both the American Cancer Society and the Leukemia and Lymphoma Society, and is on the editorial advisory board of the Journal of Experimental Medicine.
Dr. Schoenberger is a leader in understanding the immunobiology of CD4 + and CD8 + Tcell responses with particular expertise on the generation and maintenance of immune memory by these subsets and in the key role of antigen-presenting cells (APC) in mediating antigen-specific tolerance versus immunity. His research has revealed a new mechanism for how CD4 + T cells provide the ‘help’ necessary for optimal CD8 + T cell responses via APC activation and his laboratory was the first to demonstrate the role of T cell programming in guiding the development of CD8 + T cells. More recently, he has
sought to translate his laboratory’s insights into T cell and APC biology for the personalized immunotherapy of cancer. He and his team have developed a range of novel tools and approaches for the identification of personalized tumor neoantigen targets for immunotherapeutic intervention in solid cancers including personalized cancer vaccines and adoptive cellular therapy. Clinical trials based on applying these discoveries are scheduled to begin at the UCSD Moores Cancer Center in 2018.